

sub B1
cont

Q 1 an MBL binding CDR3₁ region or a functional variant thereof of a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of hybridoma cell line_(3F8), hybridoma cell line_(2A9), and hybridoma cell line_(hMBL1.2) deposited under ATCC accession numbers HB-12621, HB-12620, and HB-12619 respectively.

a 2 33. (Amended) The composition of claim 18, wherein the composition is a pharmaceutical composition including an effective amount of the isolated MBL binding peptide for treating an MBL mediated disorder; and,
a pharmaceutically acceptable carrier.

Please ~~cancel~~ claim 35.

In the Specification:

On page 50, line 3, immediately before the phrase "We claim:", please add the following paragraph:

a 3 Deposits: Hybridoma 3F8, 2A9, and hMBL1.2 were deposited on December 4, 1998 with the American Type Culture Collection (ATCC) as ATCC Accession Nos. HB-12621, HB-12620, and HB-12619, respectively, under the terms of the Budapest Treaty.

The ATCC is a depository affording permanence of the deposit and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the public of the material so deposited will be irrevocably removed upon the granting of a patent. The material will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R §1.14 and 35 U.S.C §122. The deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five (5) years after the most recent request for the furnishing of a sample of the deposited hybridomas, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer. Applicants acknowledge its duty to replace the deposit should the depository be unable to furnish a sample when requested due to the condition of the deposit.